tag:blogger.com,1999:blog-6334453475526523597.post5056288826854373350..comments2023-11-07T10:31:25.370+00:00Comments on CoreGenomics: Roche to buy Illumina?James@cancerhttp://www.blogger.com/profile/02825715598810395734noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-6334453475526523597.post-26085586900956281772012-07-07T13:12:42.808+01:002012-07-07T13:12:42.808+01:00The overall prognosis for lung cancer is poor when...The overall prognosis for lung cancer is poor when compared with some other cancers. Survival rates for lung cancer are generally lower than those for most cancers, with an overall five-year survival rate for lung cancer of about 16% compared to 65% for colon cancer, 89% for breast cancer, and over 99% for prostate cancer.Lung Cancer Treatmenthttp://www.sfrollc.com/lung-cancer-treatmentnoreply@blogger.comtag:blogger.com,1999:blog-6334453475526523597.post-88647337204527776212012-01-26T03:05:15.102+00:002012-01-26T03:05:15.102+00:00The price of a stock at any time is what someone i...The price of a stock at any time is what someone is willing to pay for it. It is not necessarily reflective of the value of the company. Hence what Illumina sold for last summer has no bearing on what it is worth in a all-out transaction. Just ask CSCO shareholders who bought in Dec-2000 on the basis that in the very same summer the stock was worth 2x that. You can safely argue that given what was known at the time $80 was clearly unsupportable. Without diagnostic applications of genomics ILMN is not worth half of what Roche is offering to pay for it, so the big risk for Roche is whether clinical applications will ever materialize.GroovyGeekhttps://www.blogger.com/profile/02461907290773954635noreply@blogger.com